Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bryant

Showing results (591-600 of 622) with videos related to

Pageof 63
Sort By:
Cancer Research|February 11, 2025
Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic CancerJonathan M DeLiberty, Mallory K Roach, Clint A Stalnecker, et al.
Cell Death and Differentiation|July 13, 2022
Epigenetic modulators of B cell fate identified through coupled phenotype-transcriptome analysisIsabella Y Kong, Stephanie Trezise, Amanda Light, et al.
Frontiers in Immunology|June 6, 2018
Delayed Diagnosis and Complications of Predominantly Antibody Deficiencies in a Cohort of Australian AdultsCharlotte A Slade, Julian J Bosco, Tran Binh Giang, et al.
The Journal of Experimental Medicine|May 31, 2019
TCF-1 limits the formation of Tc17 cells via repression of the MAF-RORγt axisLisa A Mielke, Yang Liao, Ella Bridie Clemens, et al.
Blood|August 22, 2013
Partial IFN-γR2 deficiency is due to protein misfolding and can be rescued by inhibitors of glycosylationMarcela Moncada-Vélez, Rubén Martinez-Barricarte, Dusan Bogunovic, et al.
Cancer Research|July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic CancerKristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Blood Advances|June 8, 2021
BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropeniaEmma M Carrington, Cynthia Louis, Tobias Kratina, et al.
Cancer Research|November 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic CancerSzu-Aun Long, Haley Todd, Grace Goodhart, et al.
Science (New York, N.Y.)|June 6, 2024
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, et al.
Science Signaling|September 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancerPriya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, et al.
Pageof 63

Showing results (591-600 of 622) with videos related to

Sort By:
Pageof 63
Cancer Research|February 11, 2025
Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic CancerJonathan M DeLiberty, Mallory K Roach, Clint A Stalnecker, et al.
Cell Death and Differentiation|July 13, 2022
Epigenetic modulators of B cell fate identified through coupled phenotype-transcriptome analysisIsabella Y Kong, Stephanie Trezise, Amanda Light, et al.
Frontiers in Immunology|June 6, 2018
Delayed Diagnosis and Complications of Predominantly Antibody Deficiencies in a Cohort of Australian AdultsCharlotte A Slade, Julian J Bosco, Tran Binh Giang, et al.
The Journal of Experimental Medicine|May 31, 2019
TCF-1 limits the formation of Tc17 cells via repression of the MAF-RORγt axisLisa A Mielke, Yang Liao, Ella Bridie Clemens, et al.
Blood|August 22, 2013
Partial IFN-γR2 deficiency is due to protein misfolding and can be rescued by inhibitors of glycosylationMarcela Moncada-Vélez, Rubén Martinez-Barricarte, Dusan Bogunovic, et al.
Cancer Research|July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic CancerKristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Blood Advances|June 8, 2021
BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropeniaEmma M Carrington, Cynthia Louis, Tobias Kratina, et al.
Cancer Research|November 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic CancerSzu-Aun Long, Haley Todd, Grace Goodhart, et al.
Science (New York, N.Y.)|June 6, 2024
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, et al.
Science Signaling|September 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancerPriya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, et al.
Pageof 63